IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM
ID: 75N93024R00017Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/7380cc19eaca42b695ab9e2324bdf9de/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the Immune Epitope Database and Analysis Program, aimed at enhancing research capabilities related to infectious diseases, allergies, and autoimmunity. The program seeks to provide a comprehensive resource for researchers to explore data on antibody and T-cell epitopes, with a focus on maintaining high standards of compliance and transparency in research practices. Proposals are due by November 19, 2024, with a base performance period from October 15, 2025, to October 14, 2026, and potential extensions for up to four additional years. Interested parties can contact Brandon de White at whitebra@niaid.nih.gov or Tom Bahrami at bahramit@niaid.nih.gov for further information.

    Files
    Title
    Posted
    75N93024R00017.pdf
    The National Institutes of Health (NIH) issued a Request for Proposal (RFP) aimed at continuing support for the Immune Epitope Database and Analysis Program. The RFP outlines requirements for proposals to be submitted by 11/19/2024. This initiative provides researchers with a resource to explore data on antibody and T-cell epitopes related to infectious diseases, allergies, and autoimmunity. The document specifies the submission and evaluation process, including the necessity for offers to be registered in the System for Award Management (SAM). Key details include the base period of performance from 10/15/2025 to 10/14/2026, with options for extensions in subsequent years. Reporting requirements specify electronic submissions conforming to Section 508 standards, and continuous updates on technical progress are mandated. Special contract provisions address the protection of human subjects, NIH reproducibility policies, and acknowledgement of federal funding. The solicitation emphasizes compliance with various regulations including financial conflict of interest reporting and information security standards, highlighting the government’s commitment to transparency and accountability in its funded research activities. Overall, this RFP reflects NIH's efforts to bolster biomedical research infrastructure while safeguarding sensitive information.
    Amendment 1 75N93024R00017.pdf
    Amendment #1 to RFP-NIAID-DAIT-75N93024R00017, issued on September 17, 2024, updates the solicitation regarding a contract aimed at providing specific services outlined in the Statement of Work. The proposal due date remains unchanged, set for November 19, 2024, at 3:00 PM. This amendment primarily addresses questions from potential offerors, specifically regarding budget and effort levels. The amended section specifies that the government requires 20,800 direct labor hours for the base year and each of the first four optional years, with an additional 1,040 hours available for each subsequent level of effort if options beyond four are exercised, cumulatively totaling 31,200 hours per year. Offerors have discretion over the proposed labor mix to align with their technical approach. The document underscores the government's commitment to transparency by inviting further questions and clarifications while emphasizing the necessity for potential bidders to acknowledge receipt of the amendment to avoid rejection. This amendment represents a typical practice in federal RFPs, ensuring applicants have the latest information to appropriately prepare their proposals.
    Lifecycle
    Title
    Type
    IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM
    Currently viewing
    Solicitation
    Similar Opportunities
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 NIAID DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing medical countermeasures against infectious diseases. This opportunity encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant pathogens, and the creation of direct acting antivirals targeting viruses with pandemic potential. The initiative is critical for enhancing public health responses to emerging infectious threats and includes funding estimates of up to $8.5 million for Research Area 001 and $20 million for Research Area 002, with proposals due to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) platform, starting around November 22, 2024. For further inquiries, interested parties may contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov.
    NIAID PROFESSIONAL, SCIENTIFIC AND TECHNICAL SUPPORT SERVICES (PSTSS)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) NIAID, is seeking proposals for Professional, Scientific, and Technical Support Services (PSTSS) to assist with various research initiatives, including basic, translational, and clinical research, as well as vaccine development and laboratory research across multiple biosafety levels. The procurement aims to secure specialized expertise to enhance the effectiveness of ongoing and future research efforts critical to public health. Proposals are due by December 16, 2024, with the contract period set to commence on June 1, 2025, and potentially extend to November 30, 2030, with a total funding cap of $3 billion across all awarded contracts. Interested parties can reach out to Rosemary Gomes at Rosemary.Gomes@nih.gov or Kristel Turansky at Kristel.Turansky@nih.gov for further information.
    A--NIH NeuroBioBank Brain and Tissue Repository
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the establishment of the NIH NeuroBioBank Brain and Tissue Repository. The objective of this procurement is to create and manage contract collection sites for acquiring, storing, and distributing human brain and central nervous system tissues for research purposes, aimed at advancing the understanding of nervous system disorders. This initiative is critical for enhancing biomedical research by providing well-characterized specimens to researchers, thereby facilitating studies that could lead to improved treatments and interventions. Proposals are due by November 25, 2024, with the anticipated contract performance period starting on May 1, 2025, and extending potentially through multiple option years. Interested vendors should contact Robin D. Knightly at robin.knightly@nih.gov or call +1 301 827 5302 for further information.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Democratized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Democratized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic. This initiative aims to enhance access to clinically validated curative cell therapies for pediatric patients with rare genetic diseases by advancing quality assurance mechanisms at Academic Medical Centers. The program focuses on developing innovative solutions for small-batch manufacturing of autologous cell therapies, addressing production variability, regulatory challenges, and market failures in this critical healthcare area. Proposals are due by November 18, 2024, at 12 PM EST, with the final solicitation released on October 22, 2024. Interested parties can reach out to the designated contact via the provided email for further inquiries.
    Scientific Management and Support to the National Institute of Mental Health (NIMH) Repository and Genomics Resource (NRGR)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for scientific management and support services for the National Institute of Mental Health Repository and Genomics Resource (NRGR). The objective of this procurement is to sustain, enhance, and enrich the NRGR, which provides critical biospecimens and genomic data for research on psychiatric disorders, thereby facilitating a deeper understanding of the genetic factors associated with mental health. This initiative is vital for advancing research in the genetics of mental disorders and ensuring broad access to valuable biospecimens and data resources for the scientific community. Proposals are due by November 8, 2024, and must be submitted electronically via the NIH's eCPS system; interested parties should contact Sarah Adan at sarah.adan@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under solicitation number 75N95024R00003. The primary objective of this procurement is to acquire, analyze, create, and distribute a variety of drug compounds essential for drug abuse and addiction research, including controlled and uncontrolled substances, while ensuring compliance with DEA regulations. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement for a five-year period, aims to enhance research capabilities in the field of drug abuse, with proposals due by November 15, 2024, at 1:00 PM (Eastern Time). Interested parties should contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov for further information.
    A--Biomedical Data Computing Support Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) National Cancer Institute (NCI), is seeking qualified contractors to provide Biomedical Data Computing Support Services. The primary objective of this procurement is to manage and analyze large, complex datasets related to cancer research, supporting the Division of Cancer Epidemiology and Genetics (DCEG) in their ongoing studies both domestically and internationally. This initiative is crucial for enhancing the understanding of cancer causes and prevention through effective data management and analysis, which includes establishing communication infrastructure, managing biomedical data, and providing statistical programming and software development. The NCI anticipates awarding multiple Indefinite Delivery Indefinite Quantity (IDIQ) contracts with an ordering period from September 2025 to September 2035. Interested parties should contact Antoinette C. Robinson at antoinette.robinson@nih.gov or +1 240 276 5823 for further information and are encouraged to monitor www.SAM.gov for updates on the solicitation.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Control (CMC) services related to the development of drug substances under RFP number 75N95024R00094. The primary objective is to secure high-quality drug substances to support preclinical and Investigational New Drug (IND)-enabling studies, ensuring compliance with current Good Manufacturing Practices (cGMP) and federal regulations. This initiative is crucial for advancing therapeutic innovations and facilitating collaborations in drug development, with a total funding amount of up to $49.7 million over the contract period from September 1, 2025, to May 14, 2031. Interested parties must submit their proposals by December 3, 2024, and can direct inquiries to primary contact Samson Shifaraw at samson.shifaraw@nih.gov or secondary contact Valerie Whipple at valerie.whipple@nih.gov.
    Reagent Generation for Bioanalytical Method Development on Biologics
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources for a potential contract focused on reagent generation for bioanalytical method development related to biologics. The primary objective is to obtain information on the availability and capability of companies to generate and deliver reagents, including anti-drug antibodies, that support the quantification of novel biologic drugs in various biological matrices. This initiative is crucial for advancing drug development processes and improving success rates in preclinical stages, with the Therapeutic Development Branch (TDB) at NIH playing a pivotal role in moving therapeutic candidates through the drug development pipeline. Interested parties must submit their capability statements by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov, referencing sources sought notice number 75N95025R00007.